We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU Industry Calls for More Dialogue on Proposed Pharmacovigilance Fees
EU Industry Calls for More Dialogue on Proposed Pharmacovigilance Fees
Drug companies could pay as much as US $330,000 per authorized product to cover postmarketing assessments required by the EU’s new pharmacovigilance law, under fees proposed by European lawmakers.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor